1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Chemical Properties

Melting point	aprox. 36°C
Boiling point	128-132 °C12 mm Hg(lit.)
Density	1.001±0.06 g/cm3(Predicted)
storage temp.	Inert atmosphere,Room Temperature
solubility	Chloroform (Slightly), Dichloromethane (Slightly), Ethyl Acetate (Slightly)
form	Solid
pka	8.66±0.40(Predicted)
color	Pale Yellow to Light Yellow
Merck	13,6319
Stability	Stable. Incompatible with strong oxidizing agents.

Hazard Codes	T
Risk Statements	25-39/23/24/25
Safety Statements	45
RIDADR	UN 2811 6.1/PG 2
WGK Germany	3
RTECS	UT8358900
HazardClass	6.1(b)
PackingGroup	III
Hazardous Substances Data	28289-54-5(Hazardous Substances Data)
Toxicity	Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic.